USANA Health Sciences, Inc. — Form 10-Q Summary
Reporting period: Quarter ended April 1, 2023. The request metadata says “2022 Q1,” but the supplied filing is for 2023 Q1; verify the intended period.
Business context
USANA develops and manufactures nutrition, personal-care, and skincare products sold primarily through independent direct sellers and Preferred Customers. It reported approximately 491,000 active customers worldwide, down 11.1% year over year. Sales outside the U.S. were 89.5% of consolidated sales.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net sales | $248.4 million | $272.9 million |
| Gross profit / gross margin | $199.8 million / 80.5% | $221.5 million / 81.2% |
| Operating earnings | $26.8 million | $33.1 million |
| Net earnings | $18.4 million | $22.5 million |
| Diluted EPS | $0.95 | $1.15 |
| Operating cash flow | $12.8 million | $19.7 million |
Net sales declined 9.0%; management estimated unfavorable currency movements reduced sales by $13.3 million. Excluding currency effects, sales declined 4.1%. Gross margin fell 70 basis points. Associate incentives declined to 42.7% of sales from 43.8%, while SG&A rose to 27.0% of sales from approximately 25.2%. The effective tax rate increased to 35.5% from 32.5%.
At April 1, 2023, cash and cash equivalents were $295.5 million, total assets $605.5 million, current liabilities $130.2 million, and stockholders’ equity $455.4 million. The company had no borrowings under its $75 million revolving credit facility. Cash, cash equivalents, and restricted cash totaled $298.4 million. No shares were repurchased during the quarter; $82.8 million remained authorized for repurchases.
Changes and management commentary
Customer declines contributed to lower sales across most regions. Greater China sales fell 7.4% reported (0.8% excluding currency); Southeast Asia Pacific fell 15.4% reported (11.6% excluding currency); and Americas and Europe fell 10.7% reported (9.5% excluding currency). North Asia sales declined 1.1% reported but increased 4.5% excluding currency.
Management attributed lower earnings primarily to reduced sales and higher relative operating expenses. It cited unfavorable currency movements, lower sales leverage, and higher material costs as pressures on gross margin; improved sales mix and lower prior-year transportation costs partly offset them. Operating cash flow was lower, partly reflecting payments of accrued Associate incentives and the 2022 employee bonus.
Outlook, risks, and contingencies
The filing provides no specific earnings or revenue guidance. Management said existing cash, expected operating cash flow, and available credit should meet ordinary-course operating and capital needs for the foreseeable future. It cautioned that adverse conditions or unusual capital needs could require financing, which may not be available on favorable terms.
Management said COVID-19-related disruption and inflationary pressures continued to challenge operations; pandemic effects were expected to potentially affect the business during 2023, but their future impact was uncertain. Other highlighted risks include direct-selling regulation, China operations and restrictions on remitting funds, foreign-exchange volatility, supply-chain and raw-material disruptions, data privacy and cybersecurity, debt-covenant compliance, and litigation. Ordinary-course legal matters were disclosed; management did not expect them, individually or collectively, to materially harm financial condition, liquidity, or results, though outcomes and potential changes were uncertain. The company reported effective disclosure controls as of April 1, 2023.
Important facts for investors to verify
- Confirm whether the requested comparison period is Q1 2022 or the supplied Q1 2023 filing.
- Track active-customer trends and regional sales, especially in China, Southeast Asia Pacific, and the Americas and Europe.
- Assess whether sales, gross margin, and operating cash flow stabilize amid currency, inflation, and customer-count pressures.
- Monitor China cash-transfer restrictions, credit-facility covenants, and the company’s capital-allocation decisions.